Thus, this unique effector population can be further exploited for immunotherapy by its capacity to target different tumor cell ligands beyond the NKp30-B7H6 interaction, broadening even further their potential to target tumor cell heterogeneity. The gene discussed is NCR3LG1; the disease is neoplasm.